Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
01.07. | Sera Prognostics joins Russell 2000, Russell 3000 indexes | 1 | Seeking Alpha | ||
06.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
08.05. | Sera Prognostics GAAP EPS of -$0.25 beats by $0.02 | 1 | Seeking Alpha | ||
08.05. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
08.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2024 Financial Results | 110 | PR Newswire | SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen | |
21.03. | Earnings call: Sera Prognostics reports Q4 2023 results, eyes 2025 growth | 1 | Investing.com | ||
20.03. | Sera Prognostics GAAP EPS of -$0.25 in-line, revenue of $0.04M misses by $0.01M | 1 | Seeking Alpha | ||
20.03. | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
20.03. | Sera Prognostics: Q4 Earnings Insights | 1 | Benzinga.com | ||
20.03. | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
20.03. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
20.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2023 Financial Results | 129 | PR Newswire | SALT LAKE CITY, March 20, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen | |
19.03. | Sera Prognostics' Earnings Outlook | 1 | Benzinga.com | ||
08.11.23 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2023 Financial Results | 222 | PR Newswire | SALT LAKE CITY, Nov. 8, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen | |
09.08.23 | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2023 Financial Results | 347 | PR Newswire | SALT LAKE CITY, Aug. 9, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 0,650 | +3,83 % | EQS-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024 | EQS-Ad-hoc: Epigenomics AG / Schlagwort(e): Halbjahresergebnis
Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2024
22.07.2024 / 17:49 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
NANOREPRO | 1,830 | +0,83 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei Cherry, Heidelberger Druck, Linde, NanoRepro, PSI Software, Singulus | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
OCUGEN | 1,485 | -1,39 % | Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Novel Modifier Gene Therapy | • Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing... ► Artikel lesen | |
SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings Set to Launch First cGMP Mammalian Manufacturing Campaign | ||
AETERNA ZENTARIS | 4,910 | -0,81 % | Aeterna Zentaris Inc: Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders | TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing... ► Artikel lesen | |
VIKING THERAPEUTICS | 60,42 | -0,53 % | Adipositas-Hoffnung Viking Therapeutics: Aktie mit 24-Prozent-Kurssprung - was ist da los? | Die Aktie des US-Biotech-Unternehmens Viking Therapeutics hat am Mittwoch nach US-Börsenschluss einen kräftigen Kurssprung von 24 Prozent hinlegen können. Das Unternehmen, das insbesondere als großer... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,556 | +2,96 % | EQS-News: Defence Therapeutics Inc.: Defence Therapeutics erhält Unterstützung durch das CNRI-H-Projekt von Canadian Nuclear Laboratories zur Beschleunigung der Entwicklung seines Radioimmunokonjugat-Programms | EQS-News: Defence Therapeutics Inc.
/ Schlagwort(e): Sonstiges
DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,066 | -2,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report Second Quarter 2024 Financial Results on August 5 | ||
REDHILL BIOPHARMA | 0,370 | +2,07 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
VAXART | 0,635 | -1,17 % | Vaxart, Inc.: Vaxart Provides Business Update | - Cash runway extended into 2026 - - Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million - - Company well-capitalized to execute on multiple key clinical and... ► Artikel lesen | |
IBIO | 2,230 | +0,68 % | iBio, Inc. - 8-K, Current Report | ||
ARBUTUS BIOPHARMA | 3,632 | +1,23 % | Arbutus Biopharma Corporation: Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 | WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology... ► Artikel lesen | |
ALDEYRA | 3,856 | +1,00 % | Aldeyra Therapeutics, Inc. - 8-K, Current Report | ||
GINKGO BIOWORKS | 0,316 | -7,60 % | Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? | ||
MANNKIND | 5,338 | -0,85 % | MannKind: INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions | Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpointPatients... ► Artikel lesen |